SGLT2 Inhibitors Reduce CV Mortality, Heart Failure Hospitalizations in Patients With Heart Failure: Systematic Review and Meta-analysis

May 15-17, 2021; Virtual
In meta-analysis of 15 randomized, placebo-controlled clinical trials, SGLT2 inhibitors reduced risk of all-cause and CV mortality and risk of composite heart failure endpoint in key patient subgroups.
Format: Microsoft PowerPoint (.ppt)
File Size: 309 KB
Released: July 1, 2021

Acknowledgements

Provided by Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Merck

Related Content

From Clinical Care Options (CCO), expert commentary on new data in heart failure management from AHA 2021

Lee R. Goldberg, MD, MPH, FACC Physicians: maximum of 0.25 AMA PRA Category 1 Credits Released: December 8, 2021 Expired: December 7, 2022

From AHA 2021, new analysis from the CHIEF-HF trial of canagliflozin vs placebo in patients with heart failure, as reported by Clinical Care Options (CCO)

Released: December 3, 2021

From AHA 2021, new analysis from EMPEROR-Preserved trial of empagliflozin in patients with “true” HFpEF, as reported by Clinical Care Options (CCO)

Released: December 2, 2021

From AHA 2021, new analysis of TRED-HF trial on detecting early relapse after HF, as reported by Clinical Care Options (CCO)

Released: December 2, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue